A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY
A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
Inclusion Criteria:
Exclusion Criteria:
Hangzhou, Zhejiang 310016, China
Bologna, 40138, Italy
Nagoya, Aichi-ken 464-8681, Japan
Suntou-gun, Shizuoka 411-8777, Japan
Chiyoda-Ku, Tokyo 1010062, Japan
Itabashi-Ku, Tokyo 173-8610, Japan
Seoul, 135-710, South Korea
Seoul, 138-736, South Korea